Perspective Therapeutics

CATX · NYSE · Pharmaceutical Preparations

Perspective Therapeutics (CATX) · oqro.io/stocks/CATX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.

How this filing works

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Want the short version?

Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.

Explain this page What did insiders at CATX buy and sell in the last 90 days?Which members of Congress and which funds traded CATX recently?

Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.

Insider trades around earnings

3 open-market purchases and 0 open-market sales by insiders of CATX between Apr 4, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Nov 9, 2026.

PurchaseSale30 days before a release30 days after

Trades in the 30 days around each of the last earnings releases
Earnings release	30 days before	On the day	30 days after
Nov 9, 2026	None	None	3 purchases
Aug 10, 2026	None	None	None
May 11, 2026	None	None	None
May 4, 2026	None	None	None

Markus Puhlmann, Chief Medical Officer, Nov 12, 2026, about $30K. Bought 3 days after the company's previous earnings release on 2026-11-09Form 4
Markus Puhlmann, Chief Medical Officer, Nov 11, 2026, about $5K. Bought 2 days after the company's previous earnings release on 2026-11-09Form 4
Johan M. Spoor, Chief Executive Officer, Nov 11, 2026, about $38K. Bought 2 days after the company's previous earnings release on 2026-11-09Form 4

Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies

Insider trades · 20

Markus PuhlmannChief Medical Officer

Filed yesterday

Bought

~$35Kacross 2 transactionsin 1 filing

Traded Nov 11 – Nov 12, 2026 · largest single transaction ~$30K

Show all 2 transactions

Nov 12, 2026~$30K · 35K sh @ $0.8447
Details Official record
Nov 11, 2026~$5K · 6,000 sh @ $0.83
Details Official record

Insider buying

Johan M. SpoorChief Executive Officer

Filed 2d ago

Bought

~$38K47K sh @ $0.8073

First insider buy since Mar 2025Traded Nov 11 · filed 1 day later

Since the trade +14.3% · S&P 500 −0.7% · to Nov 13

The CEO of Perspective Therapeutics paid $38K out of pocket for Perspective Therapeutics shares. 1 other person at Perspective Therapeutics bought some too, in the same month. It was the first purchase in 20 months.

Insider buying

Juan GrahamChief Financial Officer

Filed 2y ago

Bought

~$75K33K sh @ $2.25

Traded Mar 28, 2025 · filed 4 days later

Since the trade −57.1% · S&P 500 +35.8% · to Nov 13

The CFO of Perspective Therapeutics paid $75K out of pocket for Perspective Therapeutics shares. 3 other people at Perspective Therapeutics bought some too, in the same month. Shares held went up 1649% with this purchase.

Johan M. SpoorChief Executive Officer

Filed 2y ago

Bought

~$60Kacross 2 transactionsin 1 filing

Traded Mar 28, 2025 · largest single transaction ~$49K

Show all 2 transactions

Mar 28, 2025~$49K · 22K sh @ $2.24
Details Official record

Robert F Iii WilliamsonDirector

Filed 2y ago

Bought

~$132Kacross 2 transactionsin 1 filing

Traded Mar 28 – Mar 31, 2025 · largest single transaction ~$82K

Show all 2 transactions

Mar 31, 2025~$82K · 38K sh @ $2.14
Details Official record

Insider buying

Lori A WoodsDirector

Filed 2y ago

Bought

~$50K23K sh @ $2.13

Traded Mar 31, 2025 · filed 1 day later

Since the trade −55.7% · S&P 500 +34.9% · to Nov 13

A Perspective Therapeutics director paid $50K out of pocket for Perspective Therapeutics shares. 3 other people at Perspective Therapeutics bought some too, in the same month. Shares held went up 15% with this purchase.

Insider buying

Heidi HensonDirector

Filed 2y ago

Bought

~$100K26K sh @ $3.85

Traded Dec 4, 2024 · filed 2 days later

Since the trade −74.6% · S&P 500 +24.1% · to Nov 13

A Perspective Therapeutics director paid $100K out of pocket for Perspective Therapeutics shares. 3 other people at Perspective Therapeutics bought some too, in the same month. It was the first purchase in over a year.

Insider buying

Johan M. SpoorCEO

Filed 2y ago

Bought

~$30K8,000 sh @ $3.77

Traded Dec 4, 2024 · filed the same day

Since the trade −74.6% · S&P 500 +24.1% · to Nov 13

The CEO of Perspective Therapeutics paid $30K out of pocket for Perspective Therapeutics shares. 3 other people at Perspective Therapeutics bought some too, in the same month. Shares held went up 28% with this purchase.

Jonathan Robert HuntChief Financial Officer

Filed 2y ago

Bought